Niosomas encapsulados en prazicuantel contra Schistosoma mansoni con sensibilidad reducida al prazicuantel

Eglal I. Amer , Iman Fathy Abou-El-Naga, Laila M. Boulos , Heba S. Ramadan , Salwa S. Younis, .

Palabras clave: Schistosoma mansoni, resistencia a medicamentos, liposomas, praziquantel

Resumen

Introducción. El prazicuantel es el único fármaco disponible comercialmente para la esquistosomiasis. La escasez actual de medicamentos alternativos y la falta de medidas preventivas eficaces aumentan su valor. La creciente prevalencia de la resistencia al prazicuantel bajo una presión prolongada del fármaco es, por tanto, un tema emergente.
Objetivos. Superar la tolerancia al prazicuantel mediante nanotecnología después de la inducción en laboratorio de un aislamiento de Schistosoma mansoni con sensibilidad reducida al fármaco durante la fase intramolusco.
Materiales y métodos. Los caracoles que liberaban cercarias se trataron con prazicuantel en dosis de 200 mg/kg dos veces por semana, seguidas de un intervalo de una semana, y luego se repitieron dos veces de la misma manera. La inducción exitosa de la sensibilidad reducida se confirmó in vitro mediante la reducción de la reacción de las cercarias al prazicuantel con respecto a su actividad de natación y el porcentaje de muerte en diferentes momentos de examen. El éxito en inducir una menor sensibilidad se confirmó in vitro mediante la reducción de la reacción de las cercarias al prazicuantel.
Resultados. El tratamiento oral con una dosis única de prazicuantel de 500 mg/kg en ratones infectados con cercarias con sensibilidad reducida al prazicuantel, reveló una reducción no significativa (35,1 %) de la carga total de gusanos en comparación con los ratones de control no tratados. Los niosomas encapsulados en prazicuantel inoculados por vía oral contra S. mansoni con sensibilidad reducida al prazicuantel, permitieron reestablecer con éxito la sensibilidad del patógeno al medicamento, como lo demostró la medición de diferentes parámetros en comparación con los animales infectados no tratados con parásitos con sensibilidad reducida a prazicuantel. La carga media total de gusanos fue de 1,33 ± 0,52, con una reducción estadísticamente significativa del 94,09 %, y la erradicación completa de los gusanos machos adultos. Se obtuvo un aumento notable en el porcentaje de reducción del recuento de huevos en el tejido del hígado y el intestino (97,68 % y 98,56 %, respectivamente), asociado con un aumento masivo de huevos muertos y ausencia total de estadios inmaduros.
Conclusión. Los niosomas encapsulados en prazicuantel restauraron la sensibilidad al fármaco contra gusanos adultos de S. mansoni con sensibilidad reducida al prazicuantel inducida en el laboratorio.

Descargas

Los datos de descargas todavía no están disponibles.
  • Eglal I. Amer Medical Parasitology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
  • Iman Fathy Abou-El-Naga Medical Parasitology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt http://orcid.org/0000-0003-1095-7263
  • Laila M. Boulos Medical Parasitology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
  • Heba S. Ramadan Medical Bio-Physics, Medical Research Institute, Alexandria University, Alexandria, Egypt
  • Salwa S. Younis Medical Parasitology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Referencias bibliográficas

Hotez PJ, Alvarado M, Basáñez MG, Bolliger I, Bourne R, Boussinesq M, et al. The global burden of disease study 2010: Interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8:e3265. https://doi.org/10.1371/journal.pntd.0003265

Xu J, Yu Q, Tchuenté LT, Bergquist R, Sacko M, Utzinger J, et al. Enhancing collaboration between China and African countries for schistosomiasis control. Lancet Infect Dis. 2016;16:376-83. https://doi.org/10.1016/S1473-3099(15)00360-6

Abou-El-Naga IF. Towards elimination of schistosomiasis after 5000 years of endemicity in Egypt. Acta Trop. 2018;181:112-21. https://doi.org/10.1016/j.actatropica.2018.02.005

Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg. 1999;60:932-95. https://doi.org/10.4269/ajtmh.1999.60.932

Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3:e504. https://doi.org/10.1371/journal.pntd.0000504

Greenberg RM. New approaches for understanding mechanisms of drug resistance in schistosomes, Parasitology. 2013;140:1534-46. https://doi.org/10.1017/S0031182013000231

Kovač J, Vargas M, Keiser J. In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium. Parasit Vectors. 2017;10:365. https://doi.org/10.1186/s13071-017-2293-3

Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ. Short report: Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg. 1995;53:61-2.

Pinto-Almeida A, Mendes T, Armada A, Belo S, Carrilho E, Viveiros M, Afonso A. The role of efflux pumps in Schistosoma mansoni praziquantel resistant phenotype. PLoS ONE. 2015;10:e0140147. https://doi.org/10.1371/journal.pone.0140147

Couto FF, Coelho PM, Araújo N, Kusel JR, Katz N, Jannotti-Passos LK, et al. Schistosoma mansoni: A method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails. Mem Inst Oswaldo Cruz. 2011;106:153-7. https://doi.org/10.1590/s0074-02762011000200006

Lotfy WM, Hishmat MG, El Nashar AS, Abu El Einin HM. Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni. Pharm Biol. 2015;53:1214-9. https://doi.org/10.3109/13880209.2014.970289

Kasinathan RS, Greenberg RM. Pharmacology and potential physiological significance of schistosome multidrug resistance transporters. Exp Parasitol. 2012;132:2-6. https://doi.org/10.1016/j.exppara.2011.03.004

Abou-El-Naga IF, El Kerdany ED, Mady RF, Shalaby TI, Zaytoun EM. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis. Parasitol Int. 2017;66:735-47. https://doi.org/10.1016/j.parint.2017.08.007

Yang L,Geng Y, Li H, Zhang Y, You J, Chang Y. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie. 2009;64:86-9. https://doi.org/10.1691/ph.2009.8140

15. Frezza TF, Gremião MPD, Zanotti-Magalhães EM, Magalhães LA,Souza ALR, Allegretti SM. Liposomal-praziquantel: Efficacy against Schistosoma mansoni in a preclinical assay. Acta Trop. 2013;128:70-5. https://doi.org/10.1016/j.actatropica.2013.06.011

Kolenyak-Santos F, Garnero C, de Oliveira RN, de Souza AL, Chorilli M, Allegretti SM, et al. Nanostructured lipid carriers as a strategy to improve the in vitro Schistosomiasis activity of praziquantel. J Nanosci Nanotechnol. 2015;15:761-72. https://doi.org/10.1166/jnn.2015.9186

Gupta D, Singh A, Khan AU. Nanoparticles as efflux pump and biofilm inhibitor to rejuvenate bactericidal effect of conventional antibiotics. Nanoscale Res Lett. 2017;12:454. https://doi.org/10.1186/s11671-017-2222-6

Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: Present situation and prospects for the future. Int J Nanomedicine. 2017;12:1227-49. https://doi.org/10.2147/IJN.S121956

Zhang D, Kong YY, Sun JH, Huo SJ, Zhou M, Gui YL, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017;12:2081-108. https://doi.org/10.2147/IJN.S128790

Moles E, Urbán P, Jiménez-Díaz MB, Viera-Morilla S, Angulo-Barturen I, Busquets MA, et al. Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy. J Control Release. 2015;210:217-29. https://doi.org/10.1016/j.jconrel.2015.05.284

Ahmad K, Rabbani G, Baig MH, lim JH, Khan ME, Lee EJ, et al. Nanoparticle-based drugs: An armament for effective anti-cancer therapy. Curr Drug Metab. 2017;19:839-46. https://doi.org/10.2174/1389200218666170823115647

Sankar V, Ruckmani K, Durga S, Jailani S. Proniosomes as drug carriers. Pak J Pharm Sci. 2010;23:103-7.

Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced Oral Bioavailability of Griseofulvin via Niosomes. AAPS PharmSciTech. 2009;10:1186-92. https://doi.org/10.1208/s12249-009-9325-z

Khan R, Irchhaiya R. Niosomes: A potential tool for novel drug delivery. J Pharmaceut Investig. 2016;46:195-204.

Shingitha KP. A review: Niosomes a novel tool for drug delivery. Int J Appl Biol Pharm. 2015;6:3017-26.

Kulsirirat T, Rukthong P, Dechwongya P, Sathirakul K. The potential of non-ionic surfactant against P-glycoprotein efflux transporters for drug development system. J Bioequiv Bioavail. 2017;9:528-9.

Yolles TK, Moore PV, De-Ginsti DL, Ripson CA, Meleney HE. A technique for the perfusion of laboratory animals for the recovery of schistosomes. J Parasitol. 1947;33:419-26. 28. Abou-El-Naga IF, Sadaka HA, Amer EI, Diab IH, S.I. Khedr SI. Impact of the age of Biomphalaria alexandrina snails on Schistosoma mansoni transmission: modulation of the genetic outcome and the internal defense system of the snail. Mem Inst Oswaldo Cruz. 2015;110:585-95. https://doi.org/10.1590/0074-02760150016

Lewis FA, Stirewalt MA, Souza CP, Gazzinelli G. Large-scale laboratory maintenance of Schistosoma mansoni, with observations on three schistosome/snail host combinations. J Parasitol. 1986;72:813-29.

Abou-El-Naga IF, Amer EI, Boulos LM, El-Faham MH, Abou Seada NM, Younis SS. Biological and proteomic studies of Schistosoma mansoni with decreased sensitivity to

praziquantel. Comp Immunol Microbiol Infect Dis. 2019;66:101341. https://doi.org/10.1016/j.cimid.2019.101341

Liang YS, Bruce JL, Boyd DA. Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles. Proc First Sino-Am Symp. 1987;1:34-48.

Lotfy WM, Zaki A, El-Sayed SM. A study on a cercarial assay for detection of praziquantel-resistance in Alexandria (Egypt). Parasitologists United Journal. 2009;2:25-32.

Gonnert R, Andrews P. Praziquental, a new broad spectrum antischistosomal agent. Z Parasitol. 1977;52:129-50.

Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci. 2010;99:2049-60. https://doi.org/10.1002/jps.21944

Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: A controlled and novel drug delivery system. Bio Pharmaceut Bull. 2011;34:945-53. https://doi.org/10.1248/bpb.34.945

Lawrence MJ. Formation, characterization and stability of nonionic surfactant vesicles. STP Pharma Sci. 1996;6:49-60.

Kiwada H, Niimura H, Kato Y. Tissue distribution and pharmacokinetic evaluation of the targeting efficiency of synthetic alkyl glycoside vesicles. Chem Pharm Bull. 1985;33:2475-82.

Tian M, Gao Y, Liu Y, Liao Y, Xu R, Hedin NE, et al. Bis-GMA/TEGDMA Dental composites reinforced with electrospun nylon 6 nanocomposite nanofibers containing highly aligned fibrillar silicate single crystals. Polymer (Guildf). 2007;48:2720-8. https://doi.org/10.1016/j.polymer.2007.03.032

Smithers SR, Terry RT. Infection of laboratory hosts with cercaria of Schistosoma mansoni and the recovery of adult worms. Parasitology. 1965;55:695-700.

Cheever AW. Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull World Health Organ. 1968;39:328-31.

Pellegrino J, Faria J. The oogram method for the screening of drugs in schistosomiasis mansoni. Am J Trop Med Hyg. 1965;14:363-9. https://doi.org/10.4269/ajtmh.1965.14.363

Dmitrienko A, Hsu JC. Multiple testing in clinical trials. In: Kotz S, Balakrishnan N, Read CB, Vidakovic B, editors. Encyclopedia of statistical sciences. 2nd edition. Hoboken (NJ): John Wiley & Sons; 2006.

de Freitas Tallarico L, Miyasato PA, Nakano E. Rearing and maintenance of Biomphalaria glabrata (Say, 1818): Adults and embryos under laboratory conditions. Ann Aquacult Res. 2016;3:1013.

Mattos AC, Kusel JR, Pimenta PF, Coelho PM. Activity of praziquantel on in vitro transformed Schistosoma mansoni sporocysts. Mem Inst Oswaldo Cruz. 2006;101:283-7. https://doi.org/10.1590/s0074-02762006000900044

Liang YS, Coles GC, Doenhoff MJ, Southgate VR. In vitro responses of praziquantel-resistant and susceptible Schistosoma mansoni to praziquantel. Int J Parasitol. 2001;31:1227-35. https://doi:10.1166/jnn.2015.9186

Coles GC, Kinoti GK. Defining resistance in Schistosoma. Parasitol Today. 1997;13:157-8. https://doi.org/10.1016/s0169-4758(97)89815-8

Abou-El-Naga IF. Heat shock protein 70 (Hsp70) in Schistosoma mansoni and its role in decreased adult worm sensitivity to praziquantel. Parasitology. 2020;147:634-42. https://doi.org/10.1017/S0031182020000347

Abou-El-Naga IF. Schistosoma mansoni sarco/endoplasmic reticulum Ca2+ ATPases (SERCA): Role in reduced sensitivity to praziquantel. J Bioenerg Biomembr. 2020;52:397-408. https://doi.org/10.1007/s10863-020-09843-7

Hanallah S, El-Lakkany NM, Mahmoud S, Mousa M, Botros S. Altered immunoglobulin isotype profile and anti-immature worm surface immunoglobulins in mice harboring a praziquantel-resistant Schistosoma mansoni isolate. APMIS. 2003;111:1125-32. https://doi.org/10.1111/j.1600-0463.2003.apm1111208.x

Botros SS, El-Din SH, El-Lakkany NM, Sabra AN, Ebeid FA. Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities. J Parasitol. 2006;92:1344-9. https://doi.org/10.1645/GE-865R.1

Sheweita SA, Mangoura SA, El-Shemi AG. Different levels of Schistosoma mansoni infection induced changes in drug-metabolizing enzymes. J Helminthol. 1998;72:71-7. https://doi.org/10.1017/S0022149X00001012

Badawi AF, Mostafa MH. Possible mechanisms of alteration in the capacity of carcinogen-metabolizing enzymes during schistosomiasis. J Int Med Res. 1993;21:281-305. https://doi.org/10.1177/030006059302100601

Beyth N, Houri-Haddad Y, Domb A, Khan W, Hazan R. Alternative antimicrobial approach: Nano-antimicrobial materials. Evid-Based Complement Alternat Med. 2015;246012. https://doi.org/10.1155/2015/246012

Lawrence MJ. Sorbitan esters (sorbitan fatty acid esters). In: Rowe RC, Sheskey PL, Weller PL, editors. Handbook of pharmaceutical excipients, London, UK: Pharmaceutical Press; 2003.

World Health Organization & Joint FAO/WHO Expert committee on food additives. Evaluation of certain food additives: Seventy-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. Geneve: WHO; 2015. p. 124.

AL-Noshokaty TM, Aly I, Abo-Elmatty DM, Mesbah NM, Shehata AS, Etewa S. Evaluation of solid lipid nanoparticles loaded with praziquantel for treatment of Schistosoma mansoni infected rats. Res J Parasitol. 2020;15:38-46. https://doi.org/10.3923/jp.2020.38.46

Bruni N, Stella B, Giraudo L, Della Pepa C, Gastaldi D, Dosio F. Nanostructured delivery systems with improved leishmanicidal activity: A critical review. Int J Nanomedicine. 2017;12:5289-311. https://doi.org/10.2147/IJN.S140363

El-Lakkany N, Seif El-Din SH, Heikal L. Bioavailability and in vivo efficacy of a praziquantelpolyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice. Eur J Drug Metab Pharmacokinet. 2012;37:289-99. https://doi.org/10.1007/s13318-012-0089-6

Kasinathan RS, Sharma LK, Cunningham C, Webb TR, Greenberg RM. Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to praziquantel. PLoS Negl Trop Dis. 2014;8:e2865. https://doi.org/10.1371/journal.pntd.0002865

Zhao L, Zhao Y, Schwarz B, Mysliwietz J, Hartig R, Camaj P, et al. Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells. Int J Oncol. 2016;49:99-110. https://doi.org/10.3892/ijo.2016.3512

Cómo citar
1.
Amer EI, Abou-El-Naga IF, Boulos LM, Ramadan HS, Younis SS. Niosomas encapsulados en prazicuantel contra Schistosoma mansoni con sensibilidad reducida al prazicuantel. biomedica [Internet]. 1 de marzo de 2022 [citado 7 de diciembre de 2022];42(1):67-84. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/5913
Publicado
2022-03-01
Sección
Artículos originales